FDA Grants IND Approval For Phase 2a Clinical Trial Using CardioCell’s Itmsc Therapy To Treat Dilated Chronic Heart Failure
4/2/2014 10:50:40 AM
SAN DIEGO--(BUSINESS WIRE)--CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually. Preparation is underway to initiate the study, “A Phase IIa, Single-Blind, Placebo-Controlled, Crossover, Multi-Center, Randomized Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-Ischemic Etiology,” at Emory University, Northwestern University and the University of Pennsylvania in May 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by